Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/ijms23126381
Keywords
focal adhesion kinase; FAK inhibitors; anticancer compounds; medicinal chemistry; PROTAC; pyrimidines; triazines
Ask authors/readers for more resources
This review focuses on compounds that can block Focal adhesion kinase (FAK) with different potencies and mechanisms of action, as well as the emergence of new PROTAC molecules. It provides important insights into new FAK inhibitors and offers information for future investigations, particularly from a medicinal chemistry perspective.
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase over-expressed in different solid cancers. In recent years, FAK has been recognized as a new target for the development of antitumor agents, useful to contrast tumor development and metastasis formation. To date, studies on the role of FAK and FAK inhibitors are of great interest for both pharmaceutical companies and academia. This review is focused on compounds able to block FAK with different potencies and with different mechanisms of action, that have appeared in the literature since 2017. Furthermore, new emerging PROTAC molecules have appeared in the literature. This summary could improve knowledge of new FAK inhibitors and provide information for future investigations, in particular, from a medicinal chemistry point of view.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available